Related Experiment Video
Updated: Jan 13, 2026
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative
Alexandrea Brown1,2, Laura M Strickland1,2, Elise N Erman1,2
1The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham.
Background:
Approximately 10% of cancers achieve replicative immortality through a telomerase-independent mechanism of telomere maintenance, termed Alternative Lengthening of Telomeres (ALT). ALT is particularly prevalent in certain subtypes of malignant gliomas, such as IDH-mutant astrocytoma and pediatric glioblastoma, and frequently co-occurs with ATRX (ATRX chromatin remodeler) inactivating mutations. Although ALT is an adaptive mechanism through which cancer cells achieve proliferative immortality, the elevated levels of replication stress observed in ALT tumors constitute a potential therapeutic vulnerability.
Methods:
Leveraging CRISPR/Cas9 screening data from the Cancer Dependency Mapping Project, coupled with patient-derived cell lines and xenografts, we identified SMARCAL1 as a novel synthetic lethal vulnerability in ATRX-deficient glioma models that engage ALT. Using complementary molecular assays for DNA damage, telomere maintenance, and telomeric replication stress, we define the mechanisms underlying cytotoxicity induced by SMARCAL1 depletion in ALT-positive glioma cells.
Results:
Our data demonstrate the annealing helicase SMARCAL1 is a highly specific synthetical lethal vulnerability in cancers that use ALT. SMARCAL1 localizes to ALT-associated PML (Promyelocytic leukemia protein) bodies in ALT-positive glioma cell lines, including IDH-mutant astrocytomas. SMARCAL1 depletion, via doxycycline-induced RNAi, led to a hyperactivation of the ALT phenotype, high levels of DNA double-strand breaks in G2 phase, and cell death via mitotic catastrophe. In mice bearing intracranial xenografts derived from high-grade IDH-mutant astrocytoma, inducible SMARCAL1 depletion prolonged animal survival.
Conclusions:
Our findings demonstrate that the molecular processes orchestrating ALT-mediated telomere maintenance constitute a targetable synthetic lethal vulnerability that can be exploited by SMARCAL1 inhibition, thus supporting the future development of small molecule inhibitors of SMARCAL1 as anti-cancer therapeutics.
Insights
SMARCAL1 is a novel synthetic lethal vulnerability in Alternative Lengthening of Telomeres (ALT) cancers. Inhibiting SMARCAL1 in ALT-positive gliomas induces cell death and prolongs survival, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Alternative Lengthening of Telomeres (ALT) enables cancer cells to achieve immortality independently of telomerase.
- ALT is prevalent in IDH-mutant astrocytomas and pediatric glioblastomas, often associated with ATRX mutations.
- ALT tumors exhibit replication stress, presenting a potential therapeutic vulnerability.
Purpose of the Study:
- Identify novel synthetic lethal vulnerabilities in ALT-positive glioma models.
- Investigate the role of SMARCAL1 in ALT-mediated telomere maintenance and its therapeutic potential.
Main Methods:
- Utilized CRISPR/Cas9 screening data and patient-derived cell lines/xenografts.
- Employed molecular assays to assess DNA damage, telomere maintenance, and replication stress.
- Depleted SMARCAL1 using doxycycline-induced RNA interference.
Main Results:
- SMARCAL1 identified as a specific synthetic lethal vulnerability in ALT cancers.
- SMARCAL1 depletion in ALT-positive gliomas caused hyperactivated ALT phenotype, DNA double-strand breaks, and mitotic catastrophe.
- SMARCAL1 inhibition in xenograft models prolonged animal survival.
Conclusions:
- The ALT pathway presents a targetable synthetic lethal vulnerability exploitable by SMARCAL1 inhibition.
- SMARCAL1 inhibition demonstrates therapeutic potential in ALT-positive gliomas.
- Supports the development of SMARCAL1 inhibitors as anti-cancer therapeutics.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:15Replicative Cell Senescence